Tirzepatide Placebo

DRUG4 trials

Sponsors

BioAge Labs, Inc., Eli Lilly and Company, Duke University

Conditions

Idiopathic Intracranial Hypertension (IIH)ObesityOverweight

Phase 2

Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

TerminatedNCT06515418

BioAge Labs, Inc.Obesity

Start: 2024-06-27End: 2025-02-12Updated: 2025-03-13

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Active, not recruitingNCT06643728

Eli Lilly and CompanyObesity, Overweight

Start: 2024-10-21End: 2027-01-01Updated: 2026-05-26

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

WithdrawnNCT06901349

Eli Lilly and CompanyObesity, Overweight

Start: 2025-05-23End: 2025-06-10Updated: 2025-09-24

Phase 4

Tirzepatide in Idiopathic Intracranial Hypertension Trial

RecruitingNCT07191873

Duke UniversityIdiopathic Intracranial Hypertension (IIH)

Start: 2026-08-25End: 2028-08-01Target: 60Updated: 2026-09-15